Navigation Links
uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson's Disease
Date:6/21/2012

AMSTERDAM, June 21, 2012 /PRNewswire/ --

uniQure, a leader in the field of human gene therapy, announced today the signing of a collaborative agreement with two leading neurology experts to develop further a gene therapy incorporating uniQure's GDNF (glial cell derived neurotrophic factor) gene for the treatment of Parkinson's disease.

Professor Krystof Bankiewicz at the University of California, San Francisco (UCSF), a world expert in GDNF gene therapy, and Professor Howard Federoff of Georgetown University, a preeminent physician-neuroscientist, have developed a product approved to start clinical trials in the U.S. using uniQure's GDNF gene incorporated into an adeno-associated virus-2 (AAV-2) delivery vector. The GDNF gene contains the information to produce a protein necessary for the development and survival of nerve cells. The positive effect of GDNF on nerve cells has already been demonstrated in early research by uniQure in collaboration with the University of Lund, Sweden.  

UCSF entered into a collaboration with Dr. Russell Lonser, neurosurgeon and Chief of the Neurosurgical Branch of the NINDS, a division of the National Institutes of Health, to commence a Phase I study of the gene therapy in patients with Parkinson's disease. Patient enrollment is expected to begin mid-2012. Collaborating on the study will be Drs. Krystof Bankiewicz of UCSF, Howard Federoff of Georgetown University and NINDS co-investigator neurologists Drs. Mark Hallett and Walter Koroshetz.

"This agreement provides uniQure with access to the data from a Parkinson's disease GDNF clinical study conducted by two of the world's leading medical researchers in the field. If successful, we intend to manufacture the vector construct ourselves and with a partner progress the product into advanced clinical studies," said Jörn Aldag, CEO of uniQure. "GDNF has been shown to be involved in several other CNS disorders so if we reach the proof of concept stage
'/>"/>

SOURCE uniQure BV
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
2. Elsevier Collaborates with the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)
3. Elsevier Collaborates With Prophecy Healthcare to Enhance Its Staff Development Offerings for Healthcare Organizations
4. Goddard collaborates with international partners on MMS instrument
5. Ambrx Collaborates with Merck to Design and Develop Biologic Drug Conjugates
6. Gene Therapy - Technologies, Markets and Companies
7. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
8. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
9. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
10. Squamous Cell Cancer Responds to SPDT Therapy
11. Stem cell therapy reverses diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
(Date:7/30/2014)... , July 30, 2014  AtheroNova Inc. ... research and development of compounds to safely regress ... today announces that its partner, CardioNova, has accomplished ... clinical trial with AtheroNova,s lead compound, AHRO-001.  This ... the AHRO-001 Phase 1 safety trial completed in ...
(Date:7/30/2014)... CA (PRWEB) July 30, 2014 ... from the U.S. Environmental Protection Agency (EPA). This ... in developmental toxicity models, including tests designed to ... formation and the formation of connections between neurons ... of neurodifferentiation and synapse formation by environmental pollutants ...
(Date:7/29/2014)... 30, 2014 SoundConnect , ... company, is proud to announce the strategic additions ... in their Boston, Charleston and Atlanta offices. ... increased demand for hosted solutions, collaboration and mobility ... reduce cost. , SoundConnect was founded in 2004, ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2
... (Nasdaq: BNVI ) today announced financial ... "Scientific development, regulatory progress and growth accurately characterize ... chairman and chief executive officer. "We successfully laid ... is essential for the successful approval and marketing ...
... Corporation (NYSE: SGP ) is scheduled to ... first quarter on Tuesday, April 21, 2009. At ... a conference call to review results for the 2009 ... and other members of management will host the conference ...
... LLC, and Burrill & Company Collaborating on Strategic ... 12 Developer Tower Investments, LLC ("Tower"), and ... ("Burrill") today announced a formal partnership with aims ... planned development and funding related to the "shovel-ready" ...
Cached Biology Technology:Bionovo Announces 2008 Highlights and Year-End Financial Results 2Bionovo Announces 2008 Highlights and Year-End Financial Results 3Bionovo Announces 2008 Highlights and Year-End Financial Results 4Bionovo Announces 2008 Highlights and Year-End Financial Results 5Bionovo Announces 2008 Highlights and Year-End Financial Results 6Bionovo Announces 2008 Highlights and Year-End Financial Results 7Bionovo Announces 2008 Highlights and Year-End Financial Results 8Bionovo Announces 2008 Highlights and Year-End Financial Results 9Bionovo Announces 2008 Highlights and Year-End Financial Results 10Elk Run Developers Announce Partnership with Leading Life Sciences Firm 2Elk Run Developers Announce Partnership with Leading Life Sciences Firm 3Elk Run Developers Announce Partnership with Leading Life Sciences Firm 4
(Date:7/30/2014)... major interest in neuroscience. A large number of ... of Wallerian degeneration: transcription factor activation, immune response, ... responses in the distal segment of the sciatic ... in gene expression between the proximal and distal ... from Nantong University, China used microarrays to analyze ...
(Date:7/30/2014)... spinal cord injury (SCI), traumatic brain injury (TBI) and ... has been learned over the past 30 years regarding ... regulate axon growth, but this large body of information ... Lemmon and his team from University of Miami in ... but a consensus is emerging that one contributing factor ...
(Date:7/30/2014)... 3,000 pieces is still in its infant stage. But ... of major significance. "Amazingly often, we are findingin addition ... that we found in Baltic amber," explained Bonn paleontologist ... comes from the Baltic Sea region, which is almost ... e.g., the coastal regions of Mecklenburg, Poland and Belarus. ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2
... of branching - wild varieties of the plant Arabidopsis ... of this small mustard plant, a favorite of many ... strains from the polar circle or the subtropics, from ... first time by research teams from Tübingen, Germany, and ...
... discovered one way the p53 gene does what it's known ... in the June 8 issue of Molecular Cell. , ... a microRNA called miR-34a that participates in p53's uncanny ability ... genes in their nuclei. MicroRNAs are small chains of ribonucleic ...
... Aspirin didn’t pan out. Neither did two other potential ... desert shrub is now a front- runner in ongoing ... to inhibit inflammation, cancer and other destructive processes, can ... the annual meeting of the American Aging Association, University ...
Cached Biology News:One species, many genomes 2One species, many genomes 3Common cancer gene sends death order to tiny killer 2Agent slows aging in mice 2
... Concept in Microarrays: Biomedical Photometrics Inc. (Waterloo, ... (Jena, Germany) have collaborated to develop a ... System. The DNAscope AT is based ... DNAscope AT automatically reads up to six ...
... Localization in Early Drug Development with Imaging ... essential drug compound localization data in early ... imaging mass spectrometry service maps unlabeled ... images so you can localize drugs and ...
... provides a comprehensive kinase analysis service ... (PKS) peptide microarrays synthesized on Paraflo ... profiling, quantitative measurement of kinase kinetic ... comprehensive service includes preparation of your ...
Best pricing for 100mg-1.0g scales. Phosphopeptides are our specialty....
Biology Products: